167 related articles for article (PubMed ID: 36731366)
1. Tumor microenvironment targeting system for glioma treatment via fusion cell membrane coating nanotechnology.
Ma J; Dai L; Yu J; Cao H; Bao Y; Hu J; Zhou L; Yang J; Sofia A; Chen H; Wu F; Xie Z; Qian W; Zhan R
Biomaterials; 2023 Apr; 295():122026. PubMed ID: 36731366
[TBL] [Abstract][Full Text] [Related]
2. Tumor microenvironment-activated cancer cell membrane-liposome hybrid nanoparticle-mediated synergistic metabolic therapy and chemotherapy for non-small cell lung cancer.
Zhang W; Gong C; Chen Z; Li M; Li Y; Gao J
J Nanobiotechnology; 2021 Oct; 19(1):339. PubMed ID: 34689761
[TBL] [Abstract][Full Text] [Related]
3. Development of transferrin-modified poly(lactic-co-glycolic acid) nanoparticles for glioma therapy.
Mao J; Meng X; Zhao C; Yang Y; Liu G
Anticancer Drugs; 2019 Jul; 30(6):604-610. PubMed ID: 30855310
[TBL] [Abstract][Full Text] [Related]
4. Tumor-Antigen Activated Dendritic Cell Membrane-Coated Biomimetic Nanoparticles with Orchestrating Immune Responses Promote Therapeutic Efficacy against Glioma.
Ma X; Kuang L; Yin Y; Tang L; Zhang Y; Fan Q; Wang B; Dong Z; Wang W; Yin T; Wang Y
ACS Nano; 2023 Feb; 17(3):2341-2355. PubMed ID: 36688797
[TBL] [Abstract][Full Text] [Related]
5. Iguratimod encapsulated PLGA-NPs improves therapeutic outcome in glioma, glioma stem-like cells and temozolomide resistant glioma cells.
Younis M; Faming W; Hongyan Z; Mengmeng T; Hang S; Liudi Y
Nanomedicine; 2019 Nov; 22():102101. PubMed ID: 31654739
[TBL] [Abstract][Full Text] [Related]
6. Platelet-Tumor Cell Hybrid Membrane-Camouflaged Nanoparticles for Enhancing Therapy Efficacy in Glioma.
Wu L; Li Q; Deng J; Shen J; Xu W; Yang W; Chen B; Du Y; Zhang W; Ge F; Lei S; Li K; Wang Z
Int J Nanomedicine; 2021; 16():8433-8446. PubMed ID: 35002237
[TBL] [Abstract][Full Text] [Related]
7. Mesenchymal stem cells loaded with paclitaxel-poly(lactic-
Wang X; Gao J; Ouyang X; Wang J; Sun X; Lv Y
Int J Nanomedicine; 2018; 13():5231-5248. PubMed ID: 30237710
[TBL] [Abstract][Full Text] [Related]
8. Combined Delivery of Temozolomide and siPLK1 Using Targeted Nanoparticles to Enhance Temozolomide Sensitivity in Glioma.
Shi H; Sun S; Xu H; Zhao Z; Han Z; Jia J; Wu D; Lu J; Liu H; Yu R
Int J Nanomedicine; 2020; 15():3347-3362. PubMed ID: 32494134
[TBL] [Abstract][Full Text] [Related]
9. Hybrid membrane-coated nanosuspensions for multi-modal anti-glioma therapy via drug and antigen delivery.
Hao W; Cui Y; Fan Y; Chen M; Yang G; Wang Y; Yang M; Li Z; Gong W; Yang Y; Gao C
J Nanobiotechnology; 2021 Nov; 19(1):378. PubMed ID: 34801032
[TBL] [Abstract][Full Text] [Related]
10. Tumor microenvironment-responsive versatile "Trojan horse" theranostic nanoplatform for magnetic resonance imaging-guided multimodal synergistic antitumor treatment.
Huang Q; Pan Y; Wang M; Liu Z; Chen H; Wang J; Zhao Z; Zhang Y
Acta Biomater; 2022 Jul; 147():270-286. PubMed ID: 35595202
[TBL] [Abstract][Full Text] [Related]
11. Surface Functionalization of Polymeric Nanoparticles with Umbilical Cord-Derived Mesenchymal Stem Cell Membrane for Tumor-Targeted Therapy.
Yang N; Ding Y; Zhang Y; Wang B; Zhao X; Cheng K; Huang Y; Taleb M; Zhao J; Dong WF; Zhang L; Nie G
ACS Appl Mater Interfaces; 2018 Jul; 10(27):22963-22973. PubMed ID: 29905067
[TBL] [Abstract][Full Text] [Related]
12. Exploring the Potential of Nanotherapeutics in Targeting Tumor Microenvironment for Cancer Therapy.
Muntimadugu E; Kommineni N; Khan W
Pharmacol Res; 2017 Dec; 126():109-122. PubMed ID: 28511988
[TBL] [Abstract][Full Text] [Related]
13. Ligand-Modified Cell Membrane Enables the Targeted Delivery of Drug Nanocrystals to Glioma.
Chai Z; Ran D; Lu L; Zhan C; Ruan H; Hu X; Xie C; Jiang K; Li J; Zhou J; Wang J; Zhang Y; Fang RH; Zhang L; Lu W
ACS Nano; 2019 May; 13(5):5591-5601. PubMed ID: 31070352
[TBL] [Abstract][Full Text] [Related]
14. Self-assembled angiopep-2 modified lipid-poly (hypoxic radiosensitized polyprodrug) nanoparticles delivery TMZ for glioma synergistic TMZ and RT therapy.
Zong Z; Hua L; Wang Z; Xu H; Ye C; Pan B; Zhao Z; Zhang L; Lu J; Mei LH; Rutong Y
Drug Deliv; 2019 Dec; 26(1):34-44. PubMed ID: 30744436
[TBL] [Abstract][Full Text] [Related]
15. Enhanced EPR effects by tumour stromal cell mimicking nanoplatform on invasive pituitary adenoma.
Ma J; Wei Y; Zhang X; Lin L; Bao Y; Cao H; Chen H; Yu J; Yang J; Zhang Y; Lan H; Li X; Qiong H; Yang D; Yu Y; Chen J; Zhang C; Liu L; Chen L; Zhan R; Liu F
Mater Today Bio; 2024 Feb; 24():100895. PubMed ID: 38179430
[TBL] [Abstract][Full Text] [Related]
16. Microfluidic Sonication To Assemble Exosome Membrane-Coated Nanoparticles for Immune Evasion-Mediated Targeting.
Liu C; Zhang W; Li Y; Chang J; Tian F; Zhao F; Ma Y; Sun J
Nano Lett; 2019 Nov; 19(11):7836-7844. PubMed ID: 31597431
[TBL] [Abstract][Full Text] [Related]
17. Convection-enhanced delivery of temozolomide and whole cell tumor immunizations in GL261 and KR158 experimental mouse gliomas.
Enríquez Pérez J; Kopecky J; Visse E; Darabi A; Siesjö P
BMC Cancer; 2020 Jan; 20(1):7. PubMed ID: 31900109
[TBL] [Abstract][Full Text] [Related]
18. Immune cell-camouflaged surface-engineered nanotherapeutics for cancer management.
Jain N; Shahrukh S; Famta P; Shah S; Vambhurkar G; Khatri DK; Singh SB; Srivastava S
Acta Biomater; 2023 Jan; 155():57-79. PubMed ID: 36347447
[TBL] [Abstract][Full Text] [Related]
19. Enhanced Caspase-Mediated Abrogation of Autophagy by Temozolomide-Loaded and Panitumumab-Conjugated Poly(lactic-
Banstola A; Duwa R; Emami F; Jeong JH; Yook S
Mol Pharm; 2020 Nov; 17(11):4386-4400. PubMed ID: 33079558
[TBL] [Abstract][Full Text] [Related]
20. Imaging temozolomide-induced changes in the myeloid glioma microenvironment.
Foray C; Valtorta S; Barca C; Winkeler A; Roll W; Müther M; Wagner S; Gardner ML; Hermann S; Schäfers M; Grauer OM; Moresco RM; Zinnhardt B; Jacobs AH
Theranostics; 2021; 11(5):2020-2033. PubMed ID: 33500706
[No Abstract] [Full Text] [Related]
[Next] [New Search]
